Carl Icahn Keeps Buying Monro Stock Even After Poison Pill Defense
Carl Icahn isn't backing down from Monro, Inc (NASDAQ:MNRO)— even after the auto repair chain deployed takeover defenses aimed directly at him. The activist investor sharply increased his Monro stake in the fourth quarter, continuing to accumulate shares months after the company adopted a poison pill to limit his influence.
Icahn boosted his Monro holdings by 247% during the quarter, raising his position from 1.46 million shares to over 5.07 million shares as of Dec. 31, according to his latest 13F filing. The stake is now valued at roughly $102 million, cementing Icahn's position as the company's dominant shareholder.
Buying Continued Even After Poison Pill Trigger
Monro adopted its shareholder rights plan in November 2025 after Icahn rapidly built a stake approaching 17%, a level that would give him significant influence. The poison pill was designed to prevent any investor from acquiring 17.5% or more of the company without board approval.
But Icahn didn't stop there. His latest filing shows he continued accumulating shares throughout the fourth quarter, signaling conviction in the investment despite the company's defensive move.
That persistence suggests Icahn sees substantial upside potential — and may be positioning himself to influence the company's future direction.
Activist Playbook Points to Potential Strategic Push
Icahn has a long history of targeting automotive aftermarket companies, including prior investments in Pep Boys and Federal-Mogul. His activist campaigns often focus on improving operations, unlocking shareholder value, or pursuing strategic alternatives.
Monro's defensive response and Icahn's continued buying point to rising strategic tension between the investor and the company's leadership.
With Icahn now firmly established as Monro's largest shareholder and still building his position even after the poison pill, investors will be watching closely for signs of a deeper activist push that could reshape the company's trajectory.
Image created using artificial intelligence via Midjourney.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Metals fade as long yields offset cooler inflation, lower Fed odds - Kitco PM Report
Bitwise brings NEAR to Wall Street – But the chart isn’t impressed
Synopsys and OpenAI reach AI chip design partnership, stock price surges over 7%
Synopsys has signed a multi-year legally binding agreement with OpenAI to jointly develop GPT-Synopsys, a model specifically trained and fine-tuned for chip design tasks. OpenAI will pay Synopsys a subscription fee for tool licensing, and both parties will share revenue based on improvements in chip design achieved by customers using the product.
How does Wall Street view the PCE? Goldman Sachs delays expectation for Fed rate hike
After the lower-than-expected US August PCE data was released, Goldman Sachs delayed its expectation for the Federal Reserve's second rate hike from October to December, and stated that it does not rule out the possibility that the Fed may eventually decide no further hikes are necessary. "New Fed Newsletter" Timiraos noted that the PCE does not change the previously known trend of rising inflation. Currently, the market prices in a 39% probability of a rate hike in October, down from 45% before the PCE release; and a 90% probability in December. The yield on 2-year US Treasury notes dipped slightly after the PCE announcement and then rebounded, while the 10-year yield continued to rise.
Crypto prices
More
